IP Library Granted Patent US 11,083,727
Granted Patent B2
US 11,083,727 · App. 16/233,507 · Granted Aug 10, 2021

Piperidine-substituted Mnk inhibitors and methods related thereto

Inventors: Justin T. Ernst (San Diego, CA); Paul A. Sprengeler (Escondido, CA); Siegfried H. Reich (La Jolla, CA); Samuel Sperry (Encinitas, CA)
Assignee: eFFECTOR Therapeutics Inc.
A61K31/506A61P29/00A61P35/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,083,727
App. No.
16/233,507
Granted
Aug 10, 2021
Kind
B2
Abstract

The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof wherein X 1 , X 2 , R 1 , R 2 , R 3 and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula (I) compounds as well as methods for utilizing the compounds of Formula (I) and the pharmaceutically acceptable compositions of Formula (I) compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.

Claims (6)

1. A compound having the structure

or a pharmaceutically acceptable salt thereof.

2. A compound having the structure

or a pharmaceutically acceptable salt thereof.

3. A compound selected from the group consisting of

or a pharmaceutically acceptable salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2026
From: OXFORD FINANCE LLC; EFFECTOR THERAPEUTICS, INC.
To: SJP BIOTEC GMBH
Reel/Frame 074939/0717 →
SECURITY INTEREST Recorded Jul 25, 2024
From: EFFECTOR THERAPEUTICS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 068086/0538 →
Continuity (3)
Continuation 15895523 · Feb 13, 2018
Provisional Application 62458671 · Feb 14, 2017
Related Publication 20190275039A1 · Sep 12, 2019